HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

被引:0
|
作者
Paola Gallinari
Stefania Di Marco
Phillip Jones
Michele Pallaoro
Christian Steinkühler
机构
[1] Istituto di Ricerche di Biologia Molecolare “P. Angeletti”-IRBM-Merck Research Laboratories Rome,
来源
Cell Research | 2007年 / 17卷
关键词
histone deacetylase; histone; post-translational modification; transcription; histone deacetylase inhibitors; protein acetylation;
D O I
暂无
中图分类号
学科分类号
摘要
Histone deacetylases (HDACs) and histone acetyl transferases (HATs) are two counteracting enzyme families whose enzymatic activity controls the acetylation state of protein lysine residues, notably those contained in the N-terminal extensions of the core histones. Acetylation of histones affects gene expression through its influence on chromatin conformation. In addition, several non-histone proteins are regulated in their stability or biological function by the acetylation state of specific lysine residues. HDACs intervene in a multitude of biological processes and are part of a multiprotein family in which each member has its specialized functions. In addition, HDAC activity is tightly controlled through targeted recruitment, protein-protein interactions and post-translational modifications. Control of cell cycle progression, cell survival and differentiation are among the most important roles of these enzymes. Since these processes are affected by malignant transformation, HDAC inhibitors were developed as antineoplastic drugs and are showing encouraging efficacy in cancer patients.
引用
收藏
页码:195 / 211
页数:16
相关论文
共 50 条
  • [31] Editorial: Lipids, lipid oxidation, and cancer: from biology to therapeutics
    Bydlowski, Sergio P.
    Poirot, Marc
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Histone deacetylase 1 activates PU.1 gene transcription through regulating TAF9 deacetylation and transcription factor IID assembly
    Jian, Wei
    Yan, Bowen
    Huang, Suming
    Qiu, Yi
    FASEB JOURNAL, 2017, 31 (09): : 4104 - 4116
  • [33] Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics
    Arts, J
    de Schepper, S
    Van Emelen, K
    CURRENT MEDICINAL CHEMISTRY, 2003, 10 (22) : 2343 - 2350
  • [35] Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
    Zhang, Zhiying
    Zhang, Rui
    Li, Donghai
    BIOLOGICS-TARGETS & THERAPY, 2023, 17 : 113 - 128
  • [36] miR-122 and hepatocellular carcinoma: from molecular biology to therapeutics
    Fu, Xiao
    Calin, George A.
    EBIOMEDICINE, 2018, 37 : 17 - 18
  • [37] Cigarette smoke and oxidative stress alter histone acetylation and deacetylation in alveolar epithelial cells: potential mechanism in inflammatory gene transcription
    Rahman, I
    Moodie, FM
    Wickenden, JA
    Marwick, JA
    Jimenez, LA
    MacNee, W
    EUROPEAN RESPIRATORY JOURNAL, 2003, 22 : 44S - 44S
  • [38] Histone deacetylase inhibitors and cancer: from cell biology to the clinic
    Hess-Stumpp, H
    EUROPEAN JOURNAL OF CELL BIOLOGY, 2005, 84 (2-3) : 109 - 121
  • [39] Molecular biology of pancreatic cancer and implications for gene therapy
    Lemoine, NR
    GUT, 1997, 41 : A76 - A77
  • [40] Molecular biology of pancreatic cancer and implications for gene therapy
    Lemoine, NR
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 604 - 604